tislelizumab in patients with unresectable hcc demonstrates durable responses
Published 3 years ago • 412 plays • Length 2:58Download video MP4
Download video MP3
Similar videos
-
2:01
qol analyses from rationale-301 of tislelizumab vs sorafenib in hcc
-
3:14
rationale-301: elderly subgroup analysis of tislelizumab in hcc
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
3:12
tislelizumab os benefit vs sorafenib as first line treatment for unresectable hepatocellular car...
-
4:03
rationale-306: tislelizumab and chemotherapy in escc
-
3:42
imbrave050: adjuvant atezolizumab with bevacizumab in high-risk hcc
-
1:21
oreios: real-world registry of patients with unresectable hcc
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
1:57
recent immunotherapy advances in hcc management
-
1:36
cabozantinib in patients with hcc refractory to checkpoint inhibitors
-
2:40
key outcomes of the phase 1b of atezolizumab and bevacizumab for advanced hcc
-
4:46
atezo plus bev demonstrates efficacy in preventing recurrence in patients with high-risk hcc
-
1:34
emerald-1: durvalumab, bevacizumab and tace in unresectable hcc
-
1:33
peptide vaccines with icis for fibrolamellar hepatocellular carcinoma
-
1:15
philip philip, md, on the lenvatinib data in patients with unresectable hcc presented at asco 2017
-
1:56
improving outcomes in hcc with immunotherapy
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
34:29
management of hepatocellular carcinoma before transplant
-
28:11
hepatocellular carcinoma - molecular approaches to treatment